Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Creo Medical ( (GB:CREO) ) is now available.
Creo Medical Group announced a trading update for FY24, highlighting a strong performance in their core technology segment with a 74% increase in revenues. The company is transitioning from a development phase to full commercialization, with significant cost reductions implemented in the second half of 2024, leading to improved financials expected in FY25. Additionally, the sale of a 51% stake in Creo Europe to Micro-Tech for approximately €30 million has been completed, strengthening Creo’s commercial platform and funding further development of its core technology business.
More about Creo Medical
Creo Medical Group is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. These devices are designed to improve patient outcomes by using advanced energy for endoscopic procedures. The company’s flagship technology, CROMA powered by Kamaptive, integrates multi-modal energy sources to enhance surgical precision and flexibility, offering a safer and more efficient alternative for surgical procedures.
YTD Price Performance: -3.08%
Average Trading Volume: 752,696
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £77.96M
Find detailed analytics on CREO stock on TipRanks’ Stock Analysis page.
